No profile data available.
GRI Bio, Inc. (GRI) is a healthcare company in the lung treatment pharmaceuticals industry, based in La Jolla, United States, with about 3 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$11.96 million. Its market capitalization was $7.00 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
GRI Bio reported $0 in revenue for fiscal year 2025.
$7.00 million as of December 4, 2025.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Pliant Therapeutics, Inc. (PLRX), Edesa Biotech, Inc. (EDSA), aTyr Pharma, Inc. (ATYR).